On June 4, 2020 EpiVax, Inc. ("EpiVax") a Rhode Island-based company and recognized leader in the field in the field of immunogenicity assessment reported it has licensed its advanced in silico toolkit for biologics immunogenicity screening, ISPRI, to AbCellera Biologics Inc. ("AbCellera") (Press release, EpiVax, JUN 8, 2020, View Source [SID1234560893]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ISPRI toolkit allows researchers to assess and mitigate the safety and efficacy of biologic candidates in real-time. The platform enables not only the identification of T cell epitopes, but also the characterization of predicted T cell response to biologics. This ability to differentiate between inflammatory and regulatory T cell immune responses utilizing computational tools is unique to EpiVax’s platforms, ISPRI and iVAX.

AbCellera, a leading biotech company in therapeutic antibody discovery from natural immune systems, plans to utilize the ISPRI toolkit to support lead candidate selection in their antibody discovery programs.

"We are pleased to enter into this relationship with EpiVax. EpiVax is a recognized leader in the field and the addition of ISPRI to AbCellera’s discovery and engineering platforms will accelerate the advancement of promising therapeutics to clinical development" said Kevin Heyries, Head of Business Development at AbCellera.

Annie De Groot, MD, CEO/CSO of EpiVax said, "We are pleased to see AbCellera join the roster of leading pharmaceutical companies that are using ISPRI to assess preclinical immunogenicity."